aTYR PHARMA INC (ATYR) Form 10-Q — May 15, 2026
aTyr Pharma reported a net loss of $10.8 million for the first quarter of 2026, driven by $7.3 million in R&D expenses and $4.1 million in general and administrative costs. The company ended the quarter with $68.3 million in total liquidity, comprising cash, restricted cash, and available-for-sale investments, which management believes is sufficient to fund operations for at least one year. In a significant strategic development, aTyr disclosed that Kyorin Pharmaceutical terminated their collaboration agreement for efzofitimod in Japan on May 12, 2026.
Key figures
- Total Assets
- 79654000
- Cash Position
- 10008000
- Shares Outstanding
- 98051212
- Ga expenses
- 4119000
- Rd expenses
- 7317000
- Restricted cash
- 1805000
- Forfeited milestones
- 155000000
- Kyorin payments received
- 20000000
- Available for sale investments
- 56505000
Price after filing
Close on the filing date to close N calendar days later (from $0.56). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.